Mounjaro®
Starting from £179.99/mo
Start journey Learn moreConstipation is one of the more common side effects of tirzepatide, and it tends to catch people off guard — most worry about nausea, not this. The good news is that for most people it responds well to straightforward changes in diet, hydration and movement, and it often eases as the body adjusts to treatment. Mounjaro slows how quickly food moves through your gut (a mechanism behind its appetite-suppressing effect), and that slower transit time can mean stools become harder and less frequent, particularly in the first few weeks or after a dose increase. This page explains what tends to help, what to watch for, and when constipation needs medical attention. As a prescription-only medicine, Mounjaro is assessed for your individual circumstances by a clinical prescriber — if constipation is affecting you, it is always worth raising it with whoever oversees your treatment. You can read the full NHS tirzepatide page for a complete side-effect overview: NHS guidance on tirzepatide.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You've started Mounjaro, your appetite has dropped noticeably, and somewhere around day three you realise your bowels haven't caught up. It is a very common experience, and it happens for a specific reason. Tirzepatide activates both GLP-1 and GIP receptors, and one of the downstream effects is a slowdown in gastric emptying, food spends longer in your digestive system, which reduces appetite but also reduces motility further down the gut. Less movement, firmer stools, less frequent visits to the bathroom.
There is a widespread misconception that constipation on GLP-1 treatment means something is seriously wrong, or that it will only get worse as doses increase. For most people, neither is true. It tends to be most noticeable in the first two to four weeks of a new dose and then gradually eases. That doesn't mean you should simply sit it out, addressing it early is more comfortable, and there are steps worth taking straight away. You can find more detail on why this happens on our page covering whether Mounjaro causes constipation.
One other factor is easy to miss: eating less overall means less bulk in the gut, which can compound the problem. If your appetite has dropped sharply, your digestive system simply has less to work with, and our page on Mounjaro constipation explains how these combined factors interact throughout treatment. Keeping fibre and fluid intake up, even when you are eating smaller amounts, matters more than usual during treatment.
The three pillars that consistently make a difference are water, fibre and physical activity, and they work together rather than independently. Dehydration makes stools harder; inadequate fibre reduces the bulk that stimulates gut movement; being sedentary slows transit further. On Mounjaro, where transit is already slower, all three gaps compound each other.
Fluid first. Most people on GLP-1 treatment are not drinking enough water, partly because appetite suppression reduces the sensation of thirst alongside hunger. Aiming for at least 1.5 to 2 litres of plain water across the day (more in warm weather or if you are active) is a reasonable starting point. Warm drinks in the morning can also help stimulate the gastrocolic reflex, the natural signal that prompts the bowel to move after eating.
Fibre next, but increase it gradually. Going from very little to a large amount of fibre quickly can cause bloating and wind, which is the last thing anyone needs on top of GI adjustment. Soluble fibre (oats, lentils, flaxseed, fruit) and insoluble fibre (vegetables, wholegrains) both play a role. A dietitian or your prescriber can suggest appropriate amounts for your specific eating pattern. Our page on how to help constipation on Mounjaro goes into dietary strategies in more detail.
Movement matters too. Even a 20-minute walk after meals can meaningfully increase gut motility. It doesn't need to be strenuous. Many people find building this into a daily routine (a walk after lunch or after dinner) is the simplest change they can make.
If diet and hydration adjustments alone are not enough, an over-the-counter stool softener or osmotic laxative may be appropriate, but speak to a pharmacist or your prescriber before starting one, particularly if you have other health conditions or take other medicines. Details on stopping constipation on Mounjaro covers these options with appropriate caveats.
Mild constipation that responds to the measures above is manageable at home. But there are signs that need prompt medical attention, and it is important to be clear about them. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines specifically highlighting acute pancreatitis, a serious but infrequent risk. The key symptom to know is severe, persistent stomach pain, particularly pain that spreads to the back, with or without vomiting. This is not constipation discomfort. If you experience it, seek urgent medical help and tell the clinician you are taking tirzepatide. You can report suspected side effects via the MHRA Yellow Card scheme, patients can do this directly, and it is an important part of how medicines are monitored after launch.
Other symptoms to act on promptly rather than wait out: constipation accompanied by bloating that does not ease over several days, signs of dehydration (dizziness, dark urine, very infrequent urination), or constipation that has not improved at all after a week of dietary changes. Longer-term constipation that is making treatment unpleasant is also worth flagging to your prescriber, dose timing, titration pace or additional support can sometimes be adjusted.
A broader overview of side effects from tirzepatide, including less common ones, is on our Mounjaro side effects page. If you are concerned about a symptom and want to speak to someone, our contact page has details for our aftercare team.
Constipation can resurface, or worsen temporarily, each time the dose steps up. This is worth expecting rather than being surprised by. The same principles apply (water, fibre, movement) but if you have already been doing all of those, the recurrence may signal that more support is needed. Speak to your prescriber before the next scheduled dose increase if you are still finding things difficult at your current dose.
Some people find the dose progression happens faster than their gut has fully adjusted to. A prescriber may recommend staying at a dose for an additional period before moving up, which is a legitimate clinical decision and not a sign of treatment failure. Avoiding constipation by going slowly is preferable to powering through it and stopping treatment. For guidance on how dose changes work more broadly, the Mounjaro treatment overview covers the licensed titration schedule factually.
If you are not yet on treatment and are weighing up whether Mounjaro is right for you, our prescribers cover side effects including constipation as part of every consultation. Suitability and support go together, check your eligibility to begin that conversation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.